Patient
SITE002-0202
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE002 (USA) (Dr. Nolan)
consented 2026-05-06
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 5
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-02-25 (study day 111); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-01-17 (study day 72); relationship: NOT RELATED
Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-29 (study day 53); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-18 (study day 42); relationship: not assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-30 (study day 24); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.